Last reviewed · How we verify
Necator americanus Hookworm Larvae
At a glance
| Generic name | Necator americanus Hookworm Larvae |
|---|---|
| Also known as | Na-L3 |
| Sponsor | Baylor College of Medicine |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Efficacy of Na-GST-1/Alhydrogel Hookworm Vaccine Assessed by Controlled Challenge Infection (PHASE2)
- Experimental Infection of Hookworm-naïve Adults With Dermally-applied Infectious Necator Americanus Hookworm Larvae (PHASE1)
- Immune Responses in the Skin After Hookworm Infection (NA)
- Establishing a Controlled Human Hookworm Infection Model at Leiden University Medical Center (NA)
- Repeated Controlled Human Hookworm Infection (NA)
- Hookworm Therapy for Coeliac Disease (PHASE1)
- Immunisation, Treatment and Controlled Human Hookworm Infection (NA)
- Inoculating Celiac Disease Patients With the Human Hookworm Necator Americanus: Evaluating Immunity and Gluten-sensitivity (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Necator americanus Hookworm Larvae CI brief — competitive landscape report
- Necator americanus Hookworm Larvae updates RSS · CI watch RSS
- Baylor College of Medicine portfolio CI